RT Journal Article
T1 Vedolizumab response in inflammatory bowel disease. Two years of follow-up.
A1 Del Pino Bellido, Pilar
A1 Belvis Jiménez, María
A1 Castro Laria, Luisa
A1 Maldonado Pérez, María Belén
A1 Sáez Díaz, Antonia
A1 Caunedo Álvarez, Ángel
A1 Argüelles-Arias, Federico
AB vedolizumab is an α4β7 integrin antagonist. The aim of this study was to evaluate the clinical response and remission rates with vedolizumab. this was a retrospective study of inflammatory bowel disease (IBD) patients who received vedolizumab between 2016 and 2019. Response and remission rates were analyzed at three, six, 12, 18 and 24 months after induction. fifty-five patients were included. Clinical remission rates in CD and UC at three, six, 12, 18 and 24 months were 19.35 %, 26.67 %, 30.43 %, 30 %, 38.89 % and 29.17 %, 26.09 %, 19.05 %, 26.67 % and 20 %, respectively. vedolizumab is effective for induction and maintenance of clinical remission, both in Crohn's disease and ulcerative colitis.
SN 1130-0108
YR 2020
FD 2020
LK http://hdl.handle.net/10668/15814
UL http://hdl.handle.net/10668/15814
LA en
DS RISalud
RD Apr 8, 2025